Lion Biotechnologies Inc. (NASDAQ:LBIO) shares reached a new 52-week high on Monday . The company traded as high as $9.58 and last traded at $9.54, with a volume of 206,483 shares traded. The stock had previously closed at $9.05.

A number of research analysts have weighed in on the stock. Zacks Investment Research lowered shares of Lion Biotechnologies from a “buy” rating to a “hold” rating in a research report on Tuesday, August 9th. FBR & Co restated a “buy” rating on shares of Lion Biotechnologies in a report on Monday, June 6th. SunTrust Banks Inc. downgraded shares of Lion Biotechnologies from a “buy” rating to a “neutral” rating and dropped their price objective for the stock from $37.00 to $30.50 in a report on Monday, June 6th. Chardan Capital restated a “buy” rating on shares of Lion Biotechnologies in a report on Saturday, June 4th. Finally, Roth Capital restated a “buy” rating and set a $15.00 price objective on shares of Lion Biotechnologies in a report on Saturday, July 9th. Two equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. The stock presently has an average rating of “Buy” and an average target price of $19.17.

The firm’s market cap is $531.77 million. The firm’s 50 day moving average price is $8.55 and its 200-day moving average price is $6.47.

Lion Biotechnologies (NASDAQ:LBIO) last released its earnings results on Monday, August 8th. The biotechnology company reported ($0.23) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.19) by $0.04. Equities analysts expect that Lion Biotechnologies Inc. will post ($0.76) EPS for the current year.

Lion Biotechnologies, Inc is a clinical-stage biotechnology company. The Company is focused on developing and commercializing cancer immunotherapy products designed to harness the power of a patient’s own immune system to eradicate cancer cells. The Company’s lead pipeline candidate, LN-144, is an adoptive cell therapy using tumor-infiltrating lymphocytes (TIL) to treat patients with refractory metastatic melanoma.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.